|Awarded On||November 19, 2014|
|Title||Therapeutic Targeting of Skp2/Ck1 to Restore Nuclear p27|
|Award Mechanism||Bridging the Gap: Early Translational Research Awards|
|Institution/Organization||Texas A&M University System Health Science Center|
|Principal Investigator/Program Director||Cheryl Walker|
|Cancer Sites||Breast, Cervix Uteri, Kidney and Renal Pelvis, Ovary, Prostate|
Endometrial carcinoma (EndoCa) is the most common gynecologic malignancy. Over 47,000 women in the United States are diagnosed with EndoCa each year in the US, and over 8,000 women will die from this disease. Unlike other gynecological cancers, EndoCa rates are increasing, with incidence of EndoCa rising by 12% and mortality rising by 23% in the last decade. Low survival rates associated with Stage II-IV disease (69-15%) reflects the fact that current therapies are relatively ineffective, especially for high grade and/or recurrent disease, and points to the unmet medical need for new and effective therapies.
Along with breast, kidney and prostate cancer, EndoCa frequently loses (or mislocali...